Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival

Ti'ara Griffen, Morehouse School of Medicine
Eric Dammer, Emory University
Courtney D Dill, Morehouse School of Medicine
Kaylin M Carey, Morehouse School of Medicine
Corey D Young, Morehouse School of Medicine
Sha'Kayla K Nunez, Morehouse School of Medicine
Adaugo Q Ohandjo, Morehouse School of Medicine
Steven M Kornblau, Univ Texas MD Anderson Canc Ctr
James W Lillard, Morehouse School of Medicine

Journal Title: BMC MEDICAL GENOMICS
Volume: Volume 14, Number 1
Publisher: BMC | 2021-06-29, Pages 171-171
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1186/s12920-021-01012-y
Permanent URL: https://pid.emory.edu/ark:/25593/vzx0k

Final published version: http://dx.doi.org/10.1186/s12920-021-01012-y
Copyright information:

© The Author(s) 2021
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Accessed October 27, 2023 3:28 PM EDT
Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival

Ti’ara L. Griffen1, Eric B. Dammer2, Courtney D. Dill1, Kaylin M. Carey1, Corey D. Young1, Sha’Kayla K. Nunez1, Adaugo Q. Ohandjo1, Steven M. Kornblau3 and James W. Lillard Jr.1*

Abstract

Background: Chronic lymphocytic leukemia (CLL) is an indolent heme malignancy characterized by the accumulation of CD5+ CD19+ B cells and episodes of relapse. The biological signaling that influence episodes of relapse in CLL are not fully described. Here, we identify gene networks associated with CLL relapse and survival risk.

Methods: Networks were investigated by using a novel weighted gene network co-expression analysis method and examining overrepresentation of upstream regulators and signaling pathways within co-expressed transcriptome modules across clinically annotated transcriptomes from CLL patients (N = 203). Gene Ontology analysis was used to identify biological functions overrepresented in each module. Differential Expression of modules and individual genes was assessed using an ANOVA (Binet Stage A and B relapsed patients) or T-test (SF3B1 mutations). The clinical relevance of biomarker candidates was evaluated using log-rank Kaplan Meier (survival and relapse interval) and ROC tests.

Results: Eight distinct modules (M2, M3, M4, M7, M9, M10, M11, M13) were significantly correlated with relapse and differentially expressed between relapsed and non-relapsed Binet Stage A CLL patients. The biological functions of modules positively correlated with relapse were carbohydrate and mRNA metabolism, whereas negatively correlated modules to relapse were protein translation associated. Additionally, M1, M3, M7, and M13 modules negatively correlated with overall survival. CLL biomarkers BTK, BCL2, and TP53 were co-expressed, while unmutated IGHV biomarker ZAP70 and cell survival-associated NOTCH1 were co-expressed in modules positively correlated with relapse and negatively correlated with survival days.

Conclusions: This study provides novel insights into CLL relapse biology and pathways associated with known and novel biomarkers for relapse and overall survival. The modules associated with relapse and overall survival represented both known and novel pathways associated with CLL pathogenesis and can be a resource for the CLL research community. The hub genes of these modules, e.g., ARHGAP27P2, C1S, CASC2, CLEC3B, CRY1, CXCR5, FUT5, MID1IP1, and URAHP, can be studied further as new therapeutic targets or clinical markers to predict CLL patient outcomes.

*Correspondence: jllillard@msm.edu
1 Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, 720 Westview Dr SW, HG 341B, Atlanta, GA 30310, USA
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Chronic lymphocytic leukemia (CLL) is a heme malignancy characterized by the presence of CD5+ CD19+ B cells in the blood, bone marrow, and lymph node organs [1]. In 2020, CLL was predicted to occur in 21,040 new cases and lead to 4060 deaths, in the United States [2]. Recent therapy innovations have markedly improved response rates, and the duration of response for most, but patients continue to develop resistance to therapy, resulting in relapse. CLL does not have a cure and is heterogeneous in terms of progression and outcomes. The molecular mechanisms responsible for relapse are incompletely understood. Patient survival can range from a few months to several years [3]. The aggregation of B cells in the bone marrow and lymphoid organs interferes with the production of new blood, resulting in anemia, thrombocytopenia and neutropenia as well as impairing immune system integrity negatively impacting the quality of life of CLL patients. To effectively cure CLL and improve the quality of life of CLL patients, we need a better understanding of the cellular and molecular mechanisms that follow CLL initiation and lead to disease progression.

Many molecular features and biomarkers have been identified for CLL that drive disease progression or clinically prognostic. Numerous cytogenetic abnormalities with favorable and unfavorable prognostic impact are recognized. The five major mutations in CLL include the 13q (mir-15), 11q (ATM), 17p (TP53), and 6q (FOXO) deletions and Trisomy 12 (NOTCH1) [4]. The 17p, 11q, 6q, and Trisomy 12 mutations result in lower overall survival, time to first treatment, and progression free survival [4]. In the current targeted therapy era (i.e., Ibrutinib, Venetoclax), the 17p deletion is the only cytogenetic aberration used to inform treatment decisions [5]. The Ig heavy chain variable region's mutation status is prognostic with unmutated forms (U-CLL) showing enhanced B cell receptor (BCR)-signaling and being prognostically adverse in patients treated with chemotherapy [6–8]. Mutated CLL (M-CLL) cells possess a rearranged IGHV, are derived from B cells that have undergone somatic hypermutation, and have decreased BCR-signaling, which results in a more indolent disease [6]. Some cytogenetic abnormalities are more prevalent based on IGHV status (i.e., Trisomy 12) which explains distinct differences in U and M-CLL biology and outcomes [9, 10].

Although not mutated, upregulation of BCR, PI3K and BCL-2 anti-apoptotic molecules are involved in signaling pathways that drive CLL progression [11] and activate downstream effectors, e.g., JNK, ERK, mTOR, and NF-kB, which promote anti-apoptotic effects, growth, and proliferation [11–13]. These pathways are targets for therapies, e.g., BCL-2 and BTK inhibitors, venetoclax and ibrutinib, respectively [14, 15]. Even with these effective targeted therapies, CLL patients often relapse.

Relapse is a common occurrence during CLL treatment. When patients are treated with the standard fludarabine, cyclophosphamide, and rituximab (FCR) therapy, 6% of patients experience relapse within 6–12 months, and 14% within 2 years [16, 17]. The 5-year progression free survival rate of refractory/relapsed CLL patients treated with ibrutinib is 44% [18]. Previously reported factors contributing to relapse are aberrant expression of BTK (ibrutinib), and BCL-2 (venetoclax). In 17p deletion relapse cases, 80% of patients developed mutations in BTK, or PLCγ2, which cause ibrutinib to become ineffective [19]. Apart from these findings, mechanisms responsible for relapse have not been completely characterized.

This study aimed to identify the gene expression patterns associated with clinical outcomes. This is the first study to our knowledge to use a novel WGCNA, a systems biology method, to determine how these molecular signatures, across the transcriptome network, are associated with the clinical attributes of CLL. Furthermore, this study aims to contribute to understanding the biology of this disease.

Methods

Reads per kilobase of transcript per million mapped Reads (RPKM) and clinical data

CLL patient RNA-seq RPKM and clinical data were downloaded from the ICGC CLLE-ES project [20]. RNA-seq expression data was sequenced via an Illumina Hiseq 2000 sequencer and aligned with the human reference genome Gencode v7 hg19. Gene counts were estimated using a transcriptome counter program called Flux Capacitor. An overview of clinical data for 203 case samples is provided (Table 1).

Data cleaning was performed to reduce variation in the gene set, of 57,820 genes, before gene clustering analysis. This was completed by removing genes with zero RPKM values in 50% or more of the patient samples. The remaining 24,658 genes were then log₂
transformed following addition of 0.05 RPKM. Next, two outlier patients, with z-transformed sample connectivity (z.k.) measures that were three or more standard deviations from the average z.k. of the patient cohort were removed iteratively until no such outliers were detected before gene clustering. A principal component analysis was performed, using the R statistical program and Factoextra package, to assess the quality of the dataset before and after data cleaning (Fig. 1). Variance in gene expression introduced by confounding variables (sex and age), was assessed using the VariancePartitian R package.

**Table 1** Distribution of reported clinical traits among CLL patients

| Clinical traits         | Description                                      | Number of patients with reported information |
|-------------------------|--------------------------------------------------|---------------------------------------------|
| Age at diagnosis        | Age patient was when diagnosed with disease      | 203                                         |
| Survival days           | Length of time patient survived (days) since primary diagnosis | 203                                         |
| Binet stage B           | Patients diagnosed with Binet Stage B CLL        | 15/203                                      |
| Binet stage A           | Patients diagnosed with Binet Stage A CLL        | 179/203                                     |
| Binet stage C           | Patients diagnosed with Binet Stage C CLL        | 8/203                                       |
| Male                    |                                                  | 116/203                                     |
| Female                  |                                                  | 78/203                                      |
| Relapse interval        | Length of disease-free interval (days) following primary treatment | 92/203                                      |
| Relapse                 | Patients with reported relapse event             | 92/203                                      |
| Chemotherapy            | Patients who received chemotherapy as first treatment | 24/203                                      |
| No treatment            | Patients who did not receive any therapy         | 9/203                                       |
| IGHV mutated            | Patients with Immunoglobulin Heavy Chain mutations | 132/203                                     |
| IGHV unmutated          | Patients without Immunoglobulin Heavy Chain mutations | 65/203                                      |
| SF3B1 mutated           | Patients with any SNP mutations in the SF3B1 gene | 19/203                                      |
| ATM mutated             | Patients with any mutations in the ATM gene      | 18/203                                      |

These clinical traits were correlated with transcriptome module eigengenes that were identified during the Weighted Gene Co-Expression Network Analysis (WGCNA).

**Fig. 1** Principle component analysis (PCA) of CLL patient RNA-seq data before and after data cleaning steps. A The variation in the dataset before data cleaning and B represents the variation in the dataset after the data cleaning steps. The x and y axes illustrate the variation between the samples.
Gene clustering

The WGCNA R package was used to identify gene co-expression networks and correlate them with several clinical traits and characteristics. WGCNA identifies gene clusters by creating a sample dissimilarity matrix (1-topology overlap) and grouping genes that have similar expression patterns within the patient cohort. The network construction was performed using WGCNA blockwiseModules function with parameters as follows: bicor correlation, signed network module separation, maxBlockSize of 25,000, and a power achieving scale-free topology of 5.5. We used “bicor”, biweight midcorrelation, as opposed to Pearson correlation, to robustly correlate with less weight given to outlier measures [21, 22]. Due to high technical variation within RNAseq data, representing transcript abundances across samples, bicor and \( p \) values were used to summarize correlation with more robustness, a pivotal feature of the analysis. The first principal component of each module (module eigengenes) was then correlated with clinical traits (Sex, deceased, alive, relapsed, survival days, age at diagnosis, IGHV status, SF3B1 mutated, ATM mutated, remission, stable, relapse interval, Binet Stage A, and Binet Stage B). Modules for Unmutated and Mutated CLL patients were built using the same parameters except for use of different optimum soft thresholding powers (3.5 for M-CLL, 6 for U-CLL). Variance introduced by confounding variables (sex and age), in individual and module gene expression, was assessed using the VariancePartition R package.

Differential expression, ROC curve, and Kaplan–Meier analyses

Differential Expression via an ANOVA test was performed to identify gene biomarker candidates within modules over-expressed/downregulated in relapsed CLL patients. A one-way ANOVA was used to compare Binet Stage A CLL patients who relapsed (n=78) with those that did not relapse (n=102). Of the patients who relapsed, 22 received chemotherapy and 17 received chemotherapy with an anti-CD52 antibody. The remaining patients had unreported therapy information. As the sequencing data for the CLL-ES project was produced prior to the FDA approval of Ibrutinib and Venetoclax, the therapy options for these CLL patients were chemotherapy (fludarabine, cyclophosphamide, bendamustine, chlorambucil) combined with an antibody (rituximab and alemtuzumab). 18,044 genes with symbols were used for further analyses. To determine if differentially expressed genes could serve as biomarkers for relapse, a Receiver Operator Curve Analysis (ROC) was performed using the expression of the top over-expressed genes in relapse-associated modules (M4, M13, M10, M3, and M7). This analysis was performed using the easyROC web tool on the default non-parametric test setting. The control group were patients who did not experience a relapse event (n=108). Cutoff points for overall survival and relapse free survival were calculated for differentially expressed hub genes with symbols (KME of 0.7 and log fold change of 0.5 and above) from networks correlated with survival days and relapse, using the cutpointR R package. For the gene combination ROC analysis, z-transformed gene expression data was used as input to calculate prognostic ratio scores, per patient, for combinations (pairs and triplets) generated from the aforementioned candidate biomarkers and genes from modules (M2 and M11) down-regulated in relapsed patients. Prognostic ratios were calculated by dividing the expression of over-expressed genes by the expression of down-regulated genes to amplify sensitivity for relapse prediction which is denoted by changes in a sample. This analysis generated 71,359 combinations to be tested at four relapse interval time points (15 months, 18 months, 3 years, and 5 years) with the pROC R package.

Gene ontology analysis

GO Elite was used to perform a gene ontology enrichment analysis on gene symbol lists from transcripts within modules of interest to identify their functions [23]. Gene enrichment analysis involves using predefined lists classifying genes of interest into categories, such as biological processes and molecular functions, and testing for statistical overrepresentation of the category members, in this case, to gene lists based on module membership. Fisher’s exact test was used to test for over-representation or significant list overlap [24]. In addition to the standard Ensemble v6.2 database with 3 standard ontology categories, the Gene Set Enrichment Analysis (GSEA) molecular signature C2 database (v6.2) was used as a reference to identify association of network modules with the curated lists related to published studies with varying focus on health and disease, particularly cancer-dysregulated gene lists [25, 26].

Module preservation

WGCNA’s modulePreservation function was used to test whether gene correlations within the ICGC modules exist in a separate cohort. The Broad CLL RNA-seq dataset (n=93, 17,000 genes) was used as the validation set. ICGC samples in the Broad study were removed prior to data processing. The validation dataset was processed in the same manner as the ICGC dataset: outlier patient samples and genes with low expression were removed and the dataset was log2 transformed prior to module preservation analysis. The module preservation function
was also used to assess preservation of modules between regressed and unregressed ICGC data and mutated (n = 132) and unmutated ICGC CLL patients (n = 65).

Results

Systems biology defines a network of CLL co-expression modules

To assess the systems biology of CLL, the transcriptome comprising 24,658 genes across 201 CLL case samples (Table 1) were examined for co-expression modules of gene transcripts. Thirteen modules eigengenes (MEs), numbered by their rank from the largest number of genes to the smallest, M1 to M13, were identified (Fig. 2; Table 2). After MEs were identified, their relatedness was determined by an expression correlation metric and plotted as a dendrogram (Fig. 3, upper panel). M10 was closely related to M7 and M13. M8, M2, and M1 were separate but also closely related,

### Table 2 Gene networks and their number of genes

| Module number | Color       | Size  |
|---------------|-------------|-------|
| M1            | Turquoise   | 4223  |
| M2            | Blue        | 3156  |
| M3            | Brown       | 1937  |
| M4            | Yellow      | 1315  |
| M5            | Green       | 1300  |
| M6            | Red         | 1260  |
| M7            | Black       | 990   |
| M8            | Pink        | 626   |
| M9            | Magenta     | 525   |
| M10           | Purple      | 479   |
| M11           | Greenyellow | 424   |
| M12           | Tan         | 317   |
| M13           | Salmon      | 207   |

Networks number and colors are displayed from the largest to smallest size.
as were M5 and M12. The relatedness dendrogram showed M6, M11, and M9 formed a branch, as do M3 and M4 modules. Next, we asked whether the ICGC intramodule gene correlations were reproducible. This question was addressed using WGCNA’s moduleP-reservation function, the ICGC modules/dataset as a reference, and RNA-seq data from a Broad CLL study as the validation set [27]. Correlations in ten (i.e., blue, black, brown, green, greenyellow, magenta, purple, red, and turquoise) of the thirteen networks were preserved in the Broad dataset (Additional file 1).

Transcript modules associated with relapse
Association of MEs to quantitative and qualitative clinical traits is assessed by correlation, reducing the multiple testing problem. This allows the determination of which modules are candidates for molecular causality of the traits of interest in this CLL cohort (Table 1). To determine the transcriptome networks of interest associated to case-sample traits, robust correlation of the 13 MEs to 8 traits including relapse status and survival time was performed (Fig. 3, heatmap). We identified M10 ($p = 1E^{-08}$, $R = 0.34$), M7 ($p = 0.008$, $R = 0.2$), M13 ($p = 0.001$, $R = 0.23$), M3 ($p = 0.05$, $R = 0.14$), and M4 ($p = 0.003$, $R = 0.21$) as positively associated with relapse, and M2

---

**Fig. 3** Module eigengene heatmap with clinical correlates. Upper panel, Module eigengene relatedness dendrogram based on the correlation network of MEs. Lower panel. The colors (bottom) represent different co-expressed gene clusters in order of relatedness. The heatmap color scale is for bicor rho from $-1$ (anti-correlated) to $+1$, (correlated) Correlations of the module eigengenes to clinical traits (i.e., Relapse Interval, Relapse, Gender, Chemotherapy, Age at Diagnosis, Survival Time in Days, Binet Stage A, and IGHV mutated). Significant student correlation $p$ values are given within the heatmap.
Module trait heatmap correlations and can be used to determine which patients are at risk for relapse. In the ME-sample heatmap, clusters C2 and C4 have above average expression of genes in the M3 and M4 (orange dashed boxes) modules and below average expression of M1 and M2 (blue dashed boxes). Cluster C5 has inversely expression patterns as the majority of this group consists of patients who did not experience a relapse event. Thus, the expression patterns of M1–M4 are associated with relapse status.

We next assessed the relationship between M1 and M2 with M3 and M4 expression modules transcripts, using Pearson correlations to MEs (kMEs). When kME is positive and above 0.7, and higher for one module than others, this identifies a gene as representative of the ME and is consistent with that module’s membership. Such genes are considered as network hubs in a signed co-expression network. Hubs tend to be the network’s key drivers. In co-expression analysis, the directionality of cause-and-effect relationship is not determinable without external information [28, 29]. The correlation table (Additional file 3) was sorted for ranked hubs (highest-to-lowest kME transcripts within their assigned module by WGCNA clustering), and correlation coefficients were colored by a red-yellow-green heatmap scale to represent positive correlation (red) and negative correlation (green) patterns across modules. Strikingly, M1 and M2 hubs shared positive correlation to each other, and negative correlation to M3 and M4 hubs. M3 and M4 hubs were inverted in their pattern. Thus, the overall expression patterns of these modules are interlinked.

Transcript modules associated with relapse stratified by IGHV status

Previously, we observed IGHV status was a modest contributor to variance observed in several modules that were correlated with relapse. This implicated that modules associated with relapse risk may be influenced by or depend on IGHV status. To further explore this relationship, patients were separated by IGHV status and transcriptomes were analyzed separately for coexpression. The U-CLL group (n = 65) produced 17 modules (Additional file 4, A) whereas the M-CLL group (n = 132) produced 12 (Additional file 4, B). After identifying modules in both sets, we asked if IGHV status alters co-expression
network structure or not using module preservation. Modules in the network with gene expression were regressed to remove IGHV covariance and were entirely and highly preserved in the original network and vice versa (Additional file 5, A and B). Regressed network modules and their module-trait relationships can be found in Additional file 6 (B, C). Moreover, we successfully cross-validated the preservation of both sets of modules in the separate M and U-CLL networks without regression (Additional file 5, C and D), implicating that observed gene correlation patterns are retained irrespective of IGHV status. None of the modules in the U-CLL group correlated with relapse, whereas 4 (Mut-M6, Mut-M10-12) correlated with relapse (Additional file 4). We followed up with a Wilcoxon t-test between Relapsed Binet Stage A and Non-relapsed Binet Stage A patients to determine if there were significant increases/decreases in expression of modules associated with relapse. To our surprise, the unmutated IGHV brown network module (U-M3) gene expression was increased in relapsed U-CLL patients (Additional file 7, B). Similar differences in expression were observed with M-CLL’s relapse associated modules (Additional file 8, A).

Gene ontology analysis of relapse-associated modules in M-CLL revealed translation (Mut-M6), cell growth, transcription, metabolism (Mut-M10), Rho protein signal transduction (Mut-M11), chromatin organization, homeostasis, and gene expression (Mut-M12) biological functions (Additional file 9). The U-M3 module in U-CLL had similar biological functions (macromolecule metabolism, mRNA processing) in addition to RNA splicing (Additional file 10). These results suggest that relapsed U-CLL patients exhibit increased levels of expression of genes involved in RNA splicing compared to U-CLL patients that did not experience relapse; relapsing M-CLL patients also showed an increase in translation machinery transcripts.

Networks associated with known drivers of CLL

We next explored co-expression relationships of genes that have been previously shown to drive CLL progression. BTK, TP53, and BCL2 are co-expressed with genes in the M1 module, which was negatively correlated with survival days ($p=0.01$, $R=-0.18$; Additional file 3). ATM was co-expressed with 3156 genes in the M2 module. ZAP70 and NOTCH1 were in the M7 and M13 modules. CXCR5 is co-expressed with genes in the M4 module. CD38, CXCL13, MCL1, and SF3B1 were not co-expressed with any genes. We noted CXCL13, CD38, MCL1, and SF3B1 did not fall into a module due to the lack of strong co-expression with over 30 gene products. However, we identified modules associated with the SF3B1 mutation status in all CLL and separately U and M-CLL patient networks. From the analysis of all CLL patients, the purple (M10) and green-yellow (M11) correlated with SF3B1 mutation status. Modules Mut-M4, Mut-M10. U-M6, and U-M10 were negatively correlated with SF3B1 mutation status. A Wilcoxon test was used to confirm decreased expression of Mut-M4 (Additional file 8, B) and U-M6 (Additional file 7, A). In U-CLL, our gene ontology results for enriched processes in U-M6 imply that SF3B1 mutations are associated with decreased proteolysis, organelle organization, mRNA transport, cell cycle regulation, and ARF protein signaling (Additional file 10). Defining overrepresented ontologies of the 13 modules’ hubs (Table 3) revealed that the key networks M1 through M4 represent ontologies including carbohydrate metabolic process (M1), mRNA metabolic process (M3), and cellular metabolic process (M4). The M2, M13, M10, M7, and M11 modules did not have any significantly overrepresented biological processes. The M9 module was overrepresented with translation elongation and termination and viral transcription and infection processes. Given that M4 hubs overrepresent the proteasome (PSMB2, UBE2B, and UBAP1), we concluded that M4 is potentially relevant to upregulated proteostasis capacity of B cells in relapsed CLL.

To identify B cell specific functional interactions between CLL biomarkers (BTK, TP53, BCL2, ZAP70, NOTCH1, CXCR5, and ATM) and hub genes of their assigned modules, we used Genome-wide Integrated Analysis of gene Networks in Tissues (GIANTv2) [30]. Deciphering these functional interactions are important, as they are implicative of mechanisms that promote CLL relapse. GIANTv2 calculates functional relationship Confidence Scores (CS) for each input gene interaction and all other gene interactions, based on what’s reported in the literature. TP53 has strong upstream interactions with M1 hub gene UNG (CS = 0.537), TUBB (CS = 0.73), PHB (CS = 0.87), MCM3 (CS = 0.95) and PPP1CA (CS = 0.97). BCL2 has high confidence upstream interactions with TP53 (CS = 0.744) and PPP1CA (CS = 0.34). ATM has upstream functional interactions with N4BP2L2 (CS = 0.89) and AKAP9 (CS = 0.86) in M3 brown. ATM has downstream functional interactions with USP34 (CS = 0.96), PNISR (CS = 0.94), TIA1 (CS = 0.91) in M1, NKT1 (CS = 0.68), and LUC7L3 (CS = 0.57) in M1. ATM’s interactions implicate signaling communication between the M1, M2, and M3 modules, which was previously implicated in Fig. 4B. ZAP70 has a downstream interaction with PTPRCAP (CS = 1), a hub gene of the M7 black module. BTK, CXCR5, and NOTCH1 did not have any high confidence interactions with the top hub genes of their assigned modules respectively (Fig. 5). These results implicate that signaling
relationships between BTK, CXCR5, NOTCH1 and their hub genes have not been characterized in the literature.

**Modules differentiating between relapsed and non-relapsed patients represent biological underpinnings of cancer**

Based on the relapse trait correlations, we hypothesized that modules with positive correlations would have elevated expression and modules with negative correlations would be down regulated in patients who experience a relapse event. This hypothesis was tested using an ANOVA-Tukey analysis (Additional file 11). Consistent with the module-trait bicor correlations to relapse (Fig. 3, heatmap), the volcano plots for Binet Stage A relapsed versus Binet Stage A non-relapsed pairwise Tukey post hoc significance confirmed elevated expression of genes in M3, M4, M7, M10, and M13 (Fig. 6A) and lower expression of M2, M9, and M11 (Fig. 6B).

A total of 1703 genes were down regulated, and 1250 genes were upregulated between the Binet stage A relapse and Binet stage A no relapse groups (Additional file 11, unfiltered full table). Biological processes associated with the upregulated genes are negative regulation of monooxygenase activity, response to stimulus, cell communication regulation, cell signaling, and epithelial-to-mesenchymal transition. We noted that

**Table 3  Functions for relapse associated networks**

| Module   | Top 5 biological processes                                                                 | FET p value |
|----------|------------------------------------------------------------------------------------------|-------------|
| **Positively correlated with relapse**                                                   |             |
| Purple   | No significant biological processes identified                                            | NA          |
| $p < 0.001$ |                                                                                           |             |
| Rho = 0.34 |                                                                                           |             |
| Salmon   | No significant biological processes identified                                            | NA          |
| $p = 0.001$ |                                                                                           |             |
| Rho = 0.23 |                                                                                           |             |
| Yellow   | Cellular macromolecule metabolic process, Proteasomal protein catabolic process, Establishment of protein localization, Intracellular transport, Positive regulation of cell cycle arrest | 2.90E−19, 2.27E−10, 5.11E−08, 4.14E−07, 1.29E−06 |
| $p = 0.003$ |                                                                                           |             |
| Rho = 0.21 |                                                                                           |             |
| Black    | No significant biological processes identified                                            | NA          |
| $p = 0.006$ |                                                                                           |             |
| Rho = 0.19 |                                                                                           |             |
| Brown    | mRNA metabolic process, Regulation of macromolecule metabolism, Modification-dependent macromolecule catabolic process, RNA splicing regulation, Cellular metabolism process | 8.10E−11, 1.24E−09, 3.51E−09, 5.81E−09, 1.91E−08 |
| $p = 0.05$ |                                                                                           |             |
| Rho = 0.14 |                                                                                           |             |
| **Negatively correlated with relapse**                                                    |             |
| Greenyellow | No significant biological processes identified                                            | NA          |
| $p < 0.001$ |                                                                                           |             |
| Rho = −0.24 |                                                                                           |             |
| Blue     | No significant biological processes identified                                            | NA          |
| $p = 0.004$ |                                                                                           |             |
| Rho = 0.2 |                                                                                           |             |
| Magenta  | Translational elongation, Viral transcription, Translational termination, Viral infectious cycle, Endocrine pancreas development | 1.86E−110, 1.17E−108, 1.37E−106, 1.89E−106, 1.76E−103 |
| $p = 0.005$ |                                                                                           |             |
| Rho = −0.2 |                                                                                           |             |

Networks adjacent to the red bar have positive correlations with relapse and are upregulated in Binet Stage A patients who relapsed. Networks adjacent to the blue panel are negatively correlated with relapse. The top five biological functions and adjusted $p$ values are displayed in the table. Networks with blank biological processes did not have any overrepresented biological processes based on the FET.
Fig. 5 Predicted interactions between CLL Biomarkers and hub genes in their assigned modules. The hub genes are represented by the large nodes. The smaller nodes represent the additional genes added based on signaling biology reported in the literature. The heatmap scale represents the confidence of the predicted interactions based on the B cell specific interactions. Red lines represent high confidence interactions.
CLL biomarkers ATM, CXCR5, and ZAP70 were significantly differentially expressed. However, there was no difference in expression detected for BTK, BCL2, CD38, MCL1, NOTCH1, SF3B1, and TP53. Additionally, we noted the top 5 differentially expressed genes in each relapse-associated module (Fig. 6): CRY1, CLEC3B, RMRP, FAM166A, and PRR7 (M10 purple), C4ORF48, UNC93B2, LTBR2, TNFRSF25, and TCETX1D4 (M13 salmon), LMNA, SLC7A5, TNFSF9, SLC41A2, and CKS2 (M4 yellow), RELL1, ID1, HIST1H1E, DUSP4, FUT5, and RNU2-64P (M3 brown), URAHP, MID1IP1, ZAP70, RAB4B.EGLN2, ITPKA (M7 black), RAB4B.EGLN2, ITPKA (M7 black), LDOC1 (M2 blue).

We hypothesized that the top differentially expressed genes of relapse associated modules could be used to predict relapse risk. Relapse risk was evaluated using a Receiver Operating Characteristic (ROC) analysis. Among those listed above, CRY1 (0.73), URAHP (0.716), MID1IP1 (0.708), and CLEC3B (0.706) had the highest AUC scores for prediction of relapse, considering the measure of relapse-free survival (Table 4). Additionally, we tested the capability of gene expression combinations to predict relapse risk at four time points: 15 months, 18 months, 3 years, and 5 years (Additional files 12–15). The input genes for this analysis were the relapse biomarker candidates (Table 4) in addition to down-regulated (relapse) genes in the blue (CNTNAP2, ADMA29, DFF3, APOD, HOMER3) and greenyellow (SNHG25, MACC1) modules and non-coexpressed genes (LPL, ZNF667, DMD, KANK2). We performed

### Table 4: Receiver operating curves (ROC) for genes overexpressed in relapse-associated modules

| Gene          | AUC   | Z     | p value | Module   |
|---------------|-------|-------|---------|----------|
| URAHP         | 0.71558 | 5.95301 | 0       | Black    |
| MID1IP1       | 0.70859 | 5.62656 | 0       | Black    |
| ZAP70         | 0.66843 | 4.2768  | 2.00E−05 | Black    |
| RAB4B.EGLN2   | 0.6482  | 3.93621 | 8.00E−05 | Black    |
| ITPKA         | 0.64456 | 3.7544  | 0.00017  | Black    |
| LDOC1         | 0.62717 | 3.13477 | 0.00172  | Black    |
| RELL1         | 0.6954  | 5.3149  | 0       | Brown    |
| HIST1H1E      | 0.66089 | 4.18598 | 3.00E−05 | Brown    |
| JADE3         | 0.66024 | 4.13126 | 4.00E−05 | Brown    |
| ID1           | 0.65624 | 4.03103 | 6.00E−05 | Brown    |
| FUT5          | 0.63222 | 3.39698 | 0.00068  | Brown    |
| CRY1          | 0.73077 | 6.38277 | 0       | Purple   |
| CLEC3B        | 0.70679 | 5.69858 | 0       | Purple   |
| RMRP          | 0.69482 | 4.94943 | 0       | Purple   |
| FAM166A       | 0.68297 | 4.91336 | 0       | Purple   |
| PRR7          | 0.65664 | 4.03721 | 5.00E−05 | Purple   |
| TCTEX1D4      | 0.68681 | 5.03117 | 0       | Salmon   |
| UNC93B2       | 0.68412 | 4.97913 | 0       | Salmon   |
| LTBR2         | 0.68167 | 4.81932 | 0       | Salmon   |
| C4orf48       | 0.67123 | 4.61744 | 0       | Salmon   |
| TNFRSF25      | 0.61798 | 3.10507 | 0.00233  | Salmon   |
| SLC41A2       | 0.67612 | 4.65439 | 0       | Yellow   |
| TNFSF9        | 0.66653 | 4.36275 | 1.00E−05 | Yellow   |
| SLC7A5        | 0.65574 | 4.04569 | 5.00E−05 | Yellow   |
| CKS2          | 0.61918 | 2.97625 | 0.00292  | Yellow   |
| LMNA          | 0.6013  | 2.4887  | 0.01282  | Yellow   |

Table of genes, AUC scores, and p values from ROC analysis. The input genes had AUC scores above 0.5. URAHP (0.711), MID1IP1 (0.693), and APBB2 (0.691) have the highest AUC scores. p values of zero represent significance less than 10−06.
this analysis in all CLL patients and U-CLL patients using the pROC R package. When considering all CLL patients, we found that SLC7A5 + URAHP + FAM166A/CNTNAP2 + HOMER3 + MACC1 (AUC 80.33%) is the best combination of genes considered for predicting relapse events within 15–18 months. ID1 + LPL + FUT5/SNHG25 + APOD + ADAM29, C1S + TCTEX1D4/CNTNAP2 + HOMER3 were the optimum combinations of candidates for predicting relapse within 3 (AUC 71.24%) and 5 years (AUC 74.6%), respectively.

In U-CLL, the following combinations were capable of predicting RFS within 3 (AUC 71.24%) and 5 years (AUC 74.6%), respectively. In U-CLL, the following combinations were capable of predicting RFS within 15 months, 18 months, 3 years and 5 years: CRY1 + RELL1/CNTNAP2 + HOMER3 (AUC 84.66%), SLC7A5 + URAHP + FAM166A/CNTNAP2 + HOMER3 + MACC1 (AUC 81.64%), CKS2 + FAM166A/HOMER3 + ADAM29 (AUC 79.55%), and UNC93B2 + SLC7A5/APOD + ADAM29 (AUC 82.91%).

To determine the effect of differentially expressed hub and biomarker genes on patient overall and relapse free survival outcomes, we performed a log-rank Kaplan Meier Analysis. Hub genes were selected for this analysis as they would make good therapeutic target candidates due to their capability to regulate the expression of multiple genes. Differentially expressed hub genes (p < 0.05, kME ≥ 0.7, LFC ≥ 0.5) from modules correlated with relapse (M3, M7, M10 and M13) and survival days (M3, M13, and M7) were evaluated (Additional file s 16 and 17). Hub genes from the M11, M9, M4, and M2 modules were not evaluated for RFS due to them not meeting the selection criterion. Hub genes from the M1 module were not evaluated for overall survival for the same reason. Hub genes ARHGAP27P2, HSPBP1, CASC2, and C1S along with CLL biomarkers CXCR5 and ZAP70 were prognostic for overall survival days (Additional file 16 and Fig. 7). Additionally, ATM, FUT5, and ZAP70 were prognostic for relapse free survival (Additional file 17 and Fig. 7).
Discussion

Systems biology approaches can decipher complex interactions between cancer cell intracellular, extracellular, genetic, and epigenetic networks [31]. This study applied a systems biology approach to identify gene transcript co-expression networks, driven by CLL progression factors, and correlated them to clinical outcomes. The strongly correlated modules represented both known and novel mechanisms of heme malignancy.

A novel WGCNA method was used to identify modules of transcripts from CLL patient blood sample derived RNAseq data. Co-expression networks are mathematically defined without supervision and revealed sets of genes controlled by the same transcription factors or epigenetic regulation, have the same function, and therefore are co-regulated. Module members can also be enriched with genes of the same signaling pathway [32]. WGCNA identified 13 modules and correlated their expression with clinical traits.

Out of the thirteen modules, eight modules were found to be correlated with CLL relapse. Five had positive correlations (M10, M13, M4, M7, and M3) and three demonstrated negative correlations (M11, M2, and M9) (Table 3). These eight modules provide insights on pathways relapsed CLL cells depend on to proliferate and survive. Interestingly, the M11 and M9 modules contain genes involved in translation (Table 3). These modules positively correlated with the IGHV mutated disease status and negatively correlated with relapse and chemotherapy. Previously, it has been shown that CLL patients with high expression of ribosomal and translation associated proteins have lower progression free survival and reduced chemotherapy requirements [33]. In this study, we observed lower expression of translation associated proteins in patients (M9 and M11 in Fig. 6B) who experienced relapse events consistent with the poor clinical course reported in aforementioned study. Chemotherapeutic drugs often induce ROS-induced cell death. Higher expression of translation-associated proteins has been associated with oxidative stress induced apoptosis [34, 35]. Our study’s findings concur with previous findings that detail CLL cells with higher expression of translation-associated proteins may be more sensitive to chemotherapeutic drugs.

The M13 and M7 modules contain known drivers of CLL (NOTCH1 and ZAP70) and genes that can be used as predictors of relapse (CRY1, CLEC3B, MID1IP1, and URAHP). M13 and M7 also negatively correlate with survival days and the IGHV mutated disease status and positively correlated with relapse. High expression of ZAP70 is associated with poorer survival outcomes, increased BCR signaling, and the unmutated CLL disease status [36–38]. Although the prognostic value of ZAP70 expression has been examined, the molecular pathways its expression affects have not been completely characterized. In this study, we found that ZAP70 is co-expressed with genes involved in WNT (APC, AXIN1, DVL1, FZD2, STK11, WNT10A, and WNT6) and NOTCH (CFD, FURIN, HES7, MAML1, and MIB2) signaling and endocytosis (ABCA7, AP2A1, ARHGAP27, CORO1A, EPS15L1, HOOK2, LRPI0, MARCH2, PDLIM7, RABEP2, RIN3, SCARF1, SCRIB, SH3GL1, SNX18, SPECC1L, UNC13D, and WASF2) and is significantly over-expressed in patients who relapsed (Additional file 8). Possibly, the M7 module associations are due to the fact that unmutated CLL cells have higher expression of WNT pathway genes and endocytose more antigens compared to mutated CLL cells [39]. In a subset of patients, NOTCH1 is constantly activated, often mutated, and is associated with ibrutinib resistance, poor clinical outcome and relapse [40–42]. Thus, supporting the M13 module’s negative correlation with days of survival [40, 43].

Interestingly, the M3 module displayed several genes of interest, associated with antigen presentation/receptor signaling (CD83), metabolism and apoptosis (CASP3, CASP8, RELA), DNA repair and gene instability (BRCA2, SUMO3, and KRAS), and GTP signaling/signal transduction (GNA13A and KRAS). In CLL, CD83 is overexpressed and has a role in creating an immunosuppressive environment [44–46]. DNA repair genes are also overexpressed and have been implicated in therapy resistance and relapse [47]. The M4 module contains genes involved in apoptosis (BCL2L11, BAK1, CASP7, DEDD2, DIABLO, FADD, TNF, and TNFRSF10B), the cell cycle (CDK7, CDK2, CDK9, CDK11B, and CDK11B), and chemokine signaling (CXCR5, GNA12, Rac1, PI3K3C3). During normal B cell maturation, CXCL13-CXCR5 signaling homes naïve B cells to bone marrow and lymphoid organs, at which point, the B cells undergo somatic hypermutation after antigen-specific BCR, SYK and LYN kinases are activated to promote the proliferation and survival of B cells [48]. Hence, co-expression of genes in this module increase the expression of pro-apoptotic proteins through the enhancement of NF-KB and PI3K signaling [49].

The CLL transcriptome co-expression network identified relationships between sets of MEs (Fig. 2). The genes in the M3 and M4 networks had an expression correlation rho above 0.5 and share the macromolecule metabolism biological function. Perhaps, the M3 module is closely related to the M4 module in function, because both share proteins that activate pathways represented by members of the cognate module. Previously, our laboratory treated prostate cancer cell lines with CXCL13 and observed an elevation in BRAC1, CTNNB1, ELK1,
HDAC8, ICAM1, GNA13, MAPK8, RELA, RHOD, and STAT3 phosphorylation, all of which were present in the brown and yellow modules [50]. The phosphorylation of these proteins resulted in the growth, proliferation, survival, and metastasis of prostate cancer cells.

The M10 module has genes that are involved in B cell activation (CD28, IRS2, TGFBI, TICAM1, and TNFRSF13C), myeloid cell activation (PREX1, SBN02, STXBP2, TGFBI, TICAM1), and cell proliferation (APOA1, ARHGEF1, BRD4, CHRM4, CITED2, E4F1, EMP1, ERF, IRS2, JUNB, KLF10, MMP14, MYC, NF2, and TGFBI). CLL cells daily depend on interactions with their microenvironment which consists of T cells, dendritic cells, myeloid support cells (NLCs) and myeloid suppressor cells which support the growth and survival of CLL cells. The presence of myeloid derived suppressor cells is correlated with poor clinical outcomes and disease progression [51, 52]. Hence, the expression levels of genes in M10 could potentially serve as markers for CLL progression.

The M2 module has genes involved in bone mineralization (ACVR2B, BMP6, BMPRIA, P2RX7, TGFBI3) and cell adhesion (CDH26, FAT2, KIAA0319, PCDH12, PCDHGA1, PCDHGA10, PCDHGAI1, PCDHGAI2, PCDHGAI3, PCDHGB7, and PCDHGC3). Bone loss is a regular occurrence in several types of cancer, including CLL [53]. It is attributed to the increased production of osteoclasts by CLL cells and the effects of chemotherapy on dividing cells [53, 54]. Perhaps the genes in M2 are down-regulated due to CLL cells remodeling their bone marrow microenvironment.

Although M1 did not associate with relapse, this module is of interest due to its association with biomarkers of CLL (i.e., BTK, TP53, BCL2). BCR-signaling is known to activate PI3K/AKT, MEK/ERK, mTOR, and NF-KB signaling to promote cell survival, migration, and proliferation in CLL. The genes in the M1 network are consistent with previous findings and provides novel interactions and functions that are associated with BCR, TP53, and BCL2 signaling. This network is overrepresented with genes involved in glutathione and carbohydrate metabolism. Enhanced glutathione production by CLL cells has been implicated in ROS generating drug resistance and increased expression of anti-apoptotic proteins, such as MCL1 [55]. Previously, it has been shown that BTK directly modulates TP53. Normally, BTK activation is increased in response to DNA damage, which ultimately phosphorylates TP53 [56]. However, based on previous findings and the M1 network, CLL cells are protected from ROS induced DNA damage and apoptosis through upregulation of glutathione, oxidoreduction, and anti-apoptotic signals. The M1 co-expression network is the first to implicate connected signaling mechanisms of BCR-signaling and glutathione metabolism. This network also suggests novel signaling mechanisms associated with CLL drug resistance.

Not only has our study shown the potential value of using gene expression modules to characterize CLL biology, but we have also shown that they can be used to stratify patients into biological sub-groups. However, our clinical conclusions on module-defined patient sub-groups are limited due to the amount of clinical information available for the ICGC cohort. We identified seven patient sub-groups after hierarchal clustering of module eigengene expression (Fig. 4B). 3 groups (clusters 2, 4, and 5) represented distinct relapse risk groups. Previously, CLL was stratified into two groups (C1 and C2) based on gene expression data [57]. In our study, we observed that ICGC clusters 2 and 4 (increased relapse risk groups) have above average expression of genes in the M3 and M4 modules and below average expression of M1 and M2 whereas Cluster 5 had the opposite expression patterns and a lower relapse risk. In the aforementioned study, group C2 had lower time to treatment intervals and increased expression of DNA splicing, mRNA transport, MAPK signaling, and organic substance response genes. Similarly, we observed the overexpression of modules with genes involved in mRNA and macromolecule signaling pathways in relapsed patients, which are the majority of the patients in ICGC clusters 2 and 4. Perhaps patients in module defined sub-groups (clusters 2 and 4) have similar biology to the C2 group.

In this study, we propose CRY1, URAHP, MID1IP1, and CLEC3B as biomarkers for relapse risk in CLL. CRY1 has been implicated as a prognostic marker progression and survival in CLL and other types of cancer, however, the role of URAHP, MID1IP1, and CLEC3B has not been explored in CLL [58, 59]. We also propose ARHGAP27P2, CASC2, CXCR5, CIS, and FUT5 as markers to predict overall survival and relapse free survival. FUT5 and CIS have been implicated as biomarkers for differentiation, proliferation, migration, and invasion in other cancers [60–62]. High CASC2 expression has been previously shown to inhibit pancreatic and ovarian cancer growth and, opposingly, contribute to breast cancer chemoresistance [63–65]. CXCL13-CXCR5 signaling is currently a biomarker for metastasis in breast and prostate cancer and mortality in colorectal cancer [66–68]. Our study is the first to report CASC2, CXCR5, and ARHGAP27P2 as biomarkers for poor overall survival prognosis in CLL. The roles of these novel biomarker genes in CLL should be further studied in silico and in vitro.
Conclusion
This is the first study to use WGCNA to identify gene signatures in CLL. Mechanisms responsible for relapse have not been completely characterized. Our study identified eight networks associated with relapse and three associated with overall survival. The modules represent known and novel pathways associated with CLL pathogenesis and relapse and can be a resource for the CLL research community. The hub genes of these modules, e.g., ARHGAP27P2, C1S, CASC2, CLEC3B, CRY1, CXCR5, FUT5, MID1IP1, and URAHP, can be studied further as new therapeutic targets or can be used as clinical markers to predict patient outcomes.

Abbreviations
BCR: B cell receptor; CLL: Chronic lymphocytic leukemia; CS: Confidence scores; GIANT: Genome-wide Integrated Analysis of gene Networks in Tissues; GO: Gene ontology; GSEA: Gene set enrichment analysis; FCR: Fludarabine, cyclophosphamide, rituximab; ICGC: International Cancer Genome Consortium; M-CLL: Mutated CLL; ME: Module eigengene; OS: Overall survival; RFS: Relapse free survival; ROC: Receiver operator curve; RPKM: Reads per kilobase per million; U-CLL: Unmutated CLL; WGCNA: Weighted Gene Co-expression Network Analysis; Z.K.: Z-transformed sample connectivity.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12920-021-01012-y.

Additional file 1. Module Preservation of ICGC CLL Modules in the Broad CLL Dataset. Median rank (left figure, y-axis) of modules determined by module preservation scores (right, y-axis) are displayed. Modules ranked closest to zero are the most preserved. The blue and red dotted lines denote cutoffs for a -log rank p value of 0.05 (blue) and p value <0.00001(red). Most modules (10 out of 13) are preserved in the Broad CLL dataset.

Additional file 2. Confounding Variable Variance. Variance scores (x-axis) of confounding variables (bold) and the top 25 genes (A, y-axis) and modules (B, y-axis) affected. At the individual gene level, age and sex contribute to less than 10% to the variance in gene expression of the top affected genes. At the module level, age at diagnosis and IGHV status are the largest contributors to variance in gene expression. 8 of 13 modules are minimally affected by confounding variables.

Additional file 3. Module eigengenes and their gene membership. Genes are listed, followed by their membership scores for each module, and lastly the module that they were assigned to.

Additional file 4. Module-trait Relationships of regressed ICGC data based on IGHV Status. Modules for unregressed (A) and regressed (B) datasets are denoted on the x-axis, traits on y-axis. The blue-white-red colors inside of the heatmap indicate positive (red), negative (blue), and no (white) correlations. The numbers, inside the heatmaps, represent the correlation test p values. WGCNA of unmutated patient data produced more modules (17 vs 11) than the mutated dataset.

Additional file 5. Module Preservation of Modules based on Regression and IGHV Status. WGCNA's Module Preservation analysis was applied according to regression (A, B) and IGHV (C, D) status. Median rank (left figure, y-axis) of modules determined by module preservation scores (right figure, y-axis) are displayed. Modules ranked closest to zero are the most preserved. The blue and red dotted lines denote cutoffs for a -log rank p value of 0.05 (blue) and p value <0.00001. Module gene correlations are preserved regardless of IGHV and Regression status.

Additional file 6. Module-Trait Heatmaps of Regressed and Unregressed ICGC Data (pdf). Modules for unregressed (A) and regressed (B, C) datasets are denoted on the x-axis, traits on y-axis. A Modules-trait relationships following regression of sex and age. B Modules-trait relationships following regression of sex, age, and IGHV status. The blue-white-red colors inside of the heatmap indicate positive (red), negative (blue), and no (white) correlations. The numbers, inside the heatmaps, represent the correlation test p values. WGCNA of unregressed data produced more modules (13 vs 11) and significant module-trait relationships (45 vs 34) than the regressed (panel B) dataset.

Additional file 7. Modules with altered expression in Unmutated CLL patients based on SF3B1 and Relapse Status. Violin plots of module eigengene (red and brown) expression (x-axis) based on SF3B1 (A) and relapse status (B). A Wilcoxon test was used to determine if module expression was altered between groups.

Additional file 8. Modules with altered expression in Mutated CLL patients based on SF3B1 and Relapse Status. Violin plots of module eigengene (red, greenyellow, purple, yellow) expression (x-axis) based on SF3B1 (A) and relapse status (B). A Wilcoxon test was used to determine if module expression was altered between groups.

Additional file 9. Gene Ontology of Relapse-Associated M-CLL network modules. Biological processes (green), molecular processes (blue), and cellular locations (brown) of M6, M10, M11, and M12 modules are displayed on the y-axis. Z-scores are on the x-axis.

Additional file 10. Gene Ontology of Relapse (U-M3) and SF3B1 (U-M6) mutation associated U-CLL modules. Biological processes (green), molecular processes (blue), and cellular locations (brown) of are displayed on the y-axis. Z-scores are on the x-axis.

Additional file 11. ANOVA Differential Expression Results. The genes are listed, followed by ANOVA F statistics, Tukey p values, log2 FPKM differences, and module names.

Additional file 12. Optimum RFS Gene Combination AUC in All ICGC CLL patients. Receiver Operator curves for Optimum biomarker gene combinations are shown for each time point: 15 months (A), 18 months (B), 3 years (C), and 5 years (D). The y-axis represents the percentage of patients who were true positives for relapse, whereas the x-axis represents the percentage of patients who were true negatives. The AUC (top left legend) for each time point is represented by a distinct color: dark orange (15 months), red (18 months), dark red (3 years), and magenta (5 years).

Additional file 13. Optimum RFS Gene Combination AUC in U-CLL patients. Receiver Operator curves for Optimum biomarker gene combinations are shown for each time point: 15 months (A), 18 months (B), 3 years (C), and 5 years (D). The y-axis represents the percentage of patients who were true positives for relapse, whereas the x-axis represents the percentage of patients who were true negatives. The AUC (top left legend) for each time point is represented by a distinct color: dark orange (15 months), red (18 months), dark red (3 years), and magenta (5 years).

Additional file 14. AUC Gene Combinations Tested in All ICGC CLL patients. Biomarker Gene combinations are listed, followed by their AUC scores for each time point (15 months, 18 months, 3 years, and 5 years).

Additional file 15. AUC Gene Combinations Tested in U-CLL ICGC CLL patients. Biomarker Gene combinations are listed, followed by their AUC scores for each time point (15 months, 18 months, 3 years, and 5 years).

Additional file 16. Overall Survival of hub genes from networks associated with survival days. OS for nine hub genes from the M3, M7, and M13 networks were evaluated. The red lines denote OS of patients with high gene expression and the blue lines refer to patients with low expression.

Additional file 17. Relapse Free Survival of hub genes from Relapse associated networks. RF5 for twelve hub genes from the M3, M7, M10, and M13 networks were evaluated. The red lines denote RF5 of patients with high gene expression and the blue lines refer to patients with low expression.
Acknowledgements
We thank ICGC and cBioPortal for use of NGS data.

Authors' contributions
TLG conceptualized and designed, acquired data, analyzed and interpreted data, and prepared manuscript. ED analyzed and interpreted data. CDD conceptualized project, interpreted data, and proofread and edited manuscript. KMC analyzed and interpreted data. SKN analyzed and interpreted data. CDY analyzed and interpreted data. AQO conceptualized project, SMK prepared manuscript. JWL conceptualized and designed and interpreted data, prepared manuscript and approved the final manuscript. All authors read and approved the final manuscript.

Funding
We thank International Cancer Genome Consortium (ICGC) for the use of NGS data. This study was funded in part by the National Cancer Institute US4CA118638 and R2SC056452 and the National Institute of General Medical Sciences R25GM085268 of the National Institutes of Health.

Availability of data and materials
The RNA sequencing datasets analyzed during the current study are the International Cancer Genome Consortium CLLE-ES project dataset (https://dcc.icgc.org/projects/CLLE-ES) and cBioPortal Broad CLL dataset (http://www.cbioportal.org/study/summary?id=cll_broad_2015).

Declarations
Ethics approval and consent to participate
Not applicable. This study was exempt from IRB approval, according to HHS policy 46.104, since we used publicly available data and materials in this study.

Consent to publish
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, 720 Westview Dr SW, HS 341B, Atlanta, GA 30331, USA. 2Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA. 3Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Received: 12 October 2020 Accepted: 10 June 2021
Published online: 29 June 2021

References
1. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. Chronic lymphocytic leukemia. Nat Rev Dis Primers. 2017;3:16096.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
3. Scarlo L, Ferrein AJ, Ghia P. Chronic lymphocytic leukemia. Ctr Rev Oncol Hematol. 2016;104:169–82.
4. Rossi D, Gaidano G. The clinical implications of gene mutations in chronic lymphocytic leukemia. Br J Cancer. 2016;114(8):849–54.
5. Buccheri V, Barreto WG, Fogliatto LM, Capia M, Marchiani M, Rocha V. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Ann Hematol. 2018;97(12):2269–78.
6. Damle RN, Wasil T, Faisi F, Giotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittram K, Kolitz J, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1848–54.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–54.
8. Visentin A, Facco M, Gurnieri C, Pagnin E, Martin V, Imbergamo S, Frezzato F, Trinacaro V, Severin F, Raggi F, et al. Prognostic and predictive effect of IGHV mutation status and load in chronic lymphocytic leukemia focus on FCR and BR treatments. Clin Lymphoma Myeloma Leuk. 2019;19(10):678–86.e674.
9. Athanasiadou A, Stamatopoulos K, Tsompanakou A, Gaitatzis M, Kaloqianidis P, Anagnostopoulos A, Fassas A, Teuzou A. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. Cancer Genet Cyto-genet. 2006;168(2):109–19.
10. Autore F, Strati P, Lauretti I, Ferrajoli A, Morphiological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica. 2018;103(6):931–8.
11. Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. Mol Med. 2018;24(1):9.
12. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592–601.
13. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313–20.
14. Honigberg LA, Smith AM, Sirisawad M, Verner E, Louny D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–80.
15. Souers AJ, Levenson ER, Boghaert ER, Ackler SL, Catron ND, Chen J, Day BD, Ding H, Enschede SH, Fairbrother WL, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.
16. Zenz T, Busch F, Fink A, Winkler D, Fischer K, Bühler A, Hoth P, Fingerle-Rowson G, Kneba M, Boettcher S, et al. Genetics of patients with F-rectory CLL or early relapse after FC or FCR: results from the CLL8 trial of the GCLLSG. Blood. 2010;116(21):2427–2427.
17. Sharma J, Flowers CR, Weiss M, Grinblatt D, Farber C, Kay N, Kipps T, Lamanna N, Pashos C, Flinn IW, et al. Patterns of care for patients with chronic lymphocytic leukemia (CLL): the connect® CLL disease registry. Blood. 2011;118(21):2864–2864.
18. O'Brien S, Furman RR, Coutre S, Flinn M, Burger JA, Blum K, Sharma J, Wierda W, Jones J, Zhao W, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–9.
19. Woyach JA, Furman RR, Liu TM, Czer H, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versace M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–94.
20. Ramsay AJ, Martinez-Trillos A, Jaess P, Rodriguez D, Kwaaijijk A, Quereda V. Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. Clin Transl Oncol. 2013;15(1):3–8.
21. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:55.
22. Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical clustering. J Stat Softw. 2012;46(11):11.
23. Zambran AC, Gaj S, Ho I, Hanspers K, Vranizan K, Evely CT, Conklin BR, Pico AR, Salomons N. GO-Elite: a flexible solution for pathway and ontology overrepresentation. Bioinformatics. 2012;28(16):2209–10.
24. Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq accounting for selection bias. Genome Biol. 2010;11(2):R14.
25. Subramanian A, Tamayo P, Mootha VK, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50.
26. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–27.
27. Landau DA, Taush E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Anagnostopoulos A, Fassas A, Teuzou A. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica. 2018;103(6):931–8.
28. Das SK, Sharma NK, Zhang B. Integrative network analysis reveals different pathophysiological mechanisms of insulin resistance among Caucasians and African Americans. BMC Med Genom. 2015;8(1):4.
29. McKenzie AT, Moyon S, Wang M, Katsoy L, Song W-M, Zhou X, Dummer EB, Duong DM, Aker J, Zhao Y, et al. Multiscale network modeling of oligo-Dendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease. Mol Neurodegener. 2017;12(1):82.
30. Wong AK, Krishnan A, Troyanskaya OG. GIANT 2.0: genome-scale integrated analysis of gene networks in tissues. Nucleic Acids Res. 2018;46(W1):W65–70.

31. Masoudi-Nejad A, Bidhoki G, Hosseini Ashtiani S, Najafi A, Bozorgmehr JH, Wang E. Cancer systems biology and modeling: microscopical scale and multiscale approaches. Semin Cancer Biol. 2015;30:60–9.

32. Gaiter C, Ding Y, French B, Tseng GC, Siblee E. Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders. Genes Brain Behav. 2014;13(1):13–24.

33. Dung J, Nuckel H, Huttman A, Kruse E, Holter T, Halfmeyer K, Fuhrer A, Rudolph R, Kalhorn N, Nusch A, et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood. 2003;101(7):2748–55.

34. Duttaroy A, Bourdeau D, Wang XL, Wang E. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1alpha. Exp Cell Res. 2000;259(1):140–8.

35. Chen E, Proestou G, Bourdeau D, Wang E. Rapid up-regulation of peptide elongation factor EF-1alpha protein levels is an immediate early event during oxidative stress-induced apoptosis. Exp Cell Res. 2000;259(1):140–8.

36. Dung J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, Moroy T, Klein-Hitpass L, Duhrensen U. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 2003;17(12):2436–43.

37. Westner A, Rosenwald A, Barry TS, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmethylated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944–51.

38. Liu Y, Wang Y, Yang J, Bi Y, Wang H. ZAP-70 in chronic lymphocytic leukemia: a meta-analysis. Clin Chim Acta. 2018;483:82–8.

39. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2004;101(9):3118–23.

40. Rosati E, Sabatini R, Rampino G, Tabilio A, D’inni M, Fettucciaro K, Bartoli A, Coaccioli S, Sprecati I, Marconi P. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113(4):856–65.

41. Puente XS, Pinyol M, Quereda V, Conde L, Ordonez GR, Villamor N, Escar- mis G, Jares P, Bea S, Gonzalez-Diaz M, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukemia. Nature. 2011;475(7354):101–5.

42. Del Papa B, Baldoni S, Dorillo E, De Falco F, Rompieti C, Cecchini D, Can- telmi MG, Sorcini D, Nogarotto M, Adamo FM, et al. Decreased NOTCH1 activation correlates with response to ibritinib in chronic lymphocytic leukemia. Clin Cancer Res. 2019;25(24):7540–53.

43. Rossi D, Rasi S, Fabbi G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cenni M, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119(2):521–9.

44. Hock BD, Haring LF, Steinkasserer A, McKenzie JL. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk Res. 2004;28(3):237–41.

45. Hock BD, Haring LF, Steinkasserer A, Taylor KG, Patton WN, McKenzie JL. Combined PER2 and CRY1 expression identifies a chronic lymphocytic leukemia subtype with unmethylated globulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944–51.

46. Novakovic KR, Grizzle WE, Lillard JW Jr. Antibody microarray analysis of signaling networks regulated by CXCL13 and CXCR5 in prostate cancer. J Proteomics Bioinform. 2012;5(8):177–84.

47. Zahran AM, Moeen SM, Thabet AF, Rayan A, Abdel-Rahim MH, Mohamed WW, Hetta HF. Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience. Leuk Lymphoma. 2020;61(7):1645–52. https://doi.org/10.1080/10428194.2020.1728747.

48. Hanna B, Ozturk S, Seiffert M. Beyond bystanders: myeloid cells in chronic lymphocytic leukemia. Mol Immunol. 2019;110:77–87.

49. Ozluewski AJ, Gutman R, Eaton CB. Increased risk of axillary fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis. Haematologica. 2016;101(12):e488–91.

50. Schmiedel BJ, Scheible CA, Nüebling T, Kopp HG, Wirths S, Azuma M, Schnei- der P, Jung G, Grosse-Hovest L, Salih HR. RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res. 2013;73(2):683–94.

51. Zhang W, Pelicano H, Yin R, Zeng J, Wen T, Ding L, Huang R. Effective elimi- nation of chronic lymphocytic leukemia cells in the stromal microenvi- ronment by a novel drug combination strategy using redox-mediated mechanisms. Mol Med Rep. 2015;12(5):7374–88.

52. Althubiti M, Rada M, Samuel J, Escorsa JM, Nazeer H, Lee KG, Lam KP, Jones GD, Barlev NA, Macp R. BTK modulators p35 activity to enhance apoptotic and senescent responses. Cancer Res. 2016;76(18):5405–14.

53. Ferreira PG, Jares P, Rico D, Gomez-Lopez G, Martinez-Trillos A, Villamor N, Ecker S, Gonzalez-Perez A, Knowles DG, Monlorg L, et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subtype in chronic lymphocytic leukemia. Genome Res. 2014;24(2):212–26.

54. Eisele L, Prinz R, Klein-Hitpass L, Nuckel H, Lowsinki K, Thomale J, Moeller LC, Duhr HU, Durig J. Combined PB2 and CR1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol. 2009;83(4):320–7.

55. Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342(1):9–18.

56. Castanon E, Soltermann A, Lopez I, Roman M, Eay C, Collantes M, Redu- mano M, Baraibar I, Lopez-Picazo JM, Roffo C, et al. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. Cancer Cells. 2017;20(43:51–53.

57. Zhao Z, Bo Z, Gong W, Guo Y. Inhibitor of differentiation 1 (Id1) in cancer and cancer therapy. Int J Med Sci. 2020;17(8):995–1005.

58. Roumenina LT, Daugan MV, Noe R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Cliche BR, Graido NA, et al. Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol Res. 2019;7(7):1091–105.

59. Xue Z, Zhu X, Teng Y. Long noncoding RNA ASC22 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer. Mol Med Rep. 2018;18(6):5173–81.

60. Zheng P, Dong L, Zhang B, Dai J, Zhang Y, Wang Y, Qin S. Long noncoding RNA ASC22 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19. Histochem Cell Biol. 2019;152(4):281–91.

61. Xue D, Wang LS, Zhou JH. Long noncoding RNA ASC22 suppresses pancreatic cancer cell growth and progression by regulating the miR24/MUC6 axis. Int J Oncol. 2020;56(2):494–507.

62. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Jr. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009;283(1):29–35.

63. Olsen RS, Nijm J, Andersson RE, Dimberg J, Wagsater D. Circulating CXCL13 and its receptor CXCR5 in prostate cancer: inflammation, immune response, and beyond. Front Endocrinol (Lausanne). 2019;10:471.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.